Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...
This Morning star Trevor Sorbie has revealed that he 'might not make it to Christmas' as he told how he has just weeks to live.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback